Cellectar biosciences announces poster presentation at the 63rd american society for hematology annual meeting and exposition

Florham park, n.j., dec. 08, 2021 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced a poster presentation featuring data from the company's ongoing phase 2 clover-1 study of iopofosine i-131 at the american society of hematology (ash) annual meeting and exposition being held virtually december 11-14, 2021.
CLRB Ratings Summary
CLRB Quant Ranking